Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Paratek's Antibiotic Nuzyra Survived 20 Years – Now For The US Launch

Oct 03 2018

• By Emily Hayes

FDA Approved

Have you checked out Scrip podcast?

New episodes every Thursday.

Related Content

Antibiotic Firms Push Ahead With cSSSI Trials, Despite Lack Of FDA Guidance

Nov 23 2009

Paratek's Omadacycline May Face Mortality Questions With Proposed Pneumonia Indication

Aug 06 2018

Paratek's Omadacycline Get US Panel OK, But CABP Mortality Remains Concern

Aug 08 2018

Paratek Sees Broad Potential For Omadacycline After Second Phase III Win

Apr 04 2017

IPO hope for post-Novartis antibiotic developer Paratek

Oct 01 2012

Related Companies

Paratek Pharmaceuticals, Inc.

Allergan plc

Almirall SA

Additional Topics

Approvals Regulation Infectious Diseases BioPharmaceutical

More from New Products

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window